The prospective trial will analyse SRSD107 to treat and prevent thromboembolic ailments. Credit: Kateryna Kon / Shutterstock.com.

Sirius Therapeutics has filed an application in Australia to commence a first-in-human clinical trial of a long-acting next-generation anticoagulant, SRSD107, to treat and prevent thromboembolic ailments. 

A double-stranded small interfering ribonucleic acid (siRNA) therapy, SRSD107 acts on coagulation factor XI (FXI) and blocks the expression of FXI protein.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This approach hinders the coagulation pathway and boosts anticoagulant/anti-thrombotic effects.

The potential anticoagulant therapeutic is the first compound of the company to enter the clinic across the globe.

Sirius Therapeutics CEO Dr Qunsheng Ji said: “We have made rapid progress in developing SRSD107 and other candidates in our pipeline since Sirius was established two years ago. 

“The exceptional durability of pharmacology and safety profile suggests SRSD107 has the potential to be a best and first-in-class FXI siRNA therapeutic. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We aspire to develop SRSD107 as a transformative medicine with a dosing schedule of once semi-annually or potentially annually for patients who need chronic anticoagulants.”

According to data from preclinical in-vivo research, a single subcutaneous dose of SRSD107 offered a nearly 100% decline in FXI levels for up to six months without any bleeding events.

Last month, the company secured $60m in a Series B funding round led by Hankang Capital.

The company intends to utilise the investment capital to progress the clinical development of its siRNA therapeutics and develop next-generation RNA delivery technologies. 

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.